EXAS•benzinga•
Exact Sciences's Return On Capital Employed Insights
Summary
According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2022 by benzinga